300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Sudan
Pakistan
Madagascar
Russian Federation
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
China
Guernsey
Cameroon
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Luxembourg
Marshall Islands
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Asia
Bermuda
Dominican Republic
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Arthurian Life Sciences, VC Fund

Arthurian Life Sciences

VC Fund

London, United Kingdom

Arthurian Life Sciences is a VC fund in London focused on Health Care and Biotechnology. Arthurian Life Sciences Ltd was established by Europe’s leading biotech entrepreneur Professor Sir Chris Evans OBE to act as General Partner of the Wales Life Sciences Investment Fund, a £100 million fund and key part of the Welsh Government’s Life Sciences initiative, as outlined by the Minister for Business, Enterprise, Technology and ScienceEdwina Hart at the BioWales Conference in 2012.The Fund had its first closing with £50 million on 28th February 2013.

Total investments:
5
Last investment:
Lead investor:
60%
Fund size:
$160M
Last fund:

Last updated:

Industries Arthurian Life Sciences invests in

Health CareBiotechnologyMedicalTherapeuticsMedical Device

Stages Arthurian Life Sciences invests in

Post-IPO EquitySeedSeries BSeries C

Countries Arthurian Life Sciences invests in

United KingdomSwitzerland

Contacts

NameEmailPhoneSocials
Brenig Preest Brenig Preest
Christopher Thomas Evans
Owen Smith

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 4 (80%)
  • Biotechnology 3 (60%)
  • Medical 2 (40%)
  • Therapeutics 2 (40%)
  • Medical Device 2 (40%)
See all 10 industries →

Stage

  • Post-IPO Equity 2 (40%)
  • Seed 1 (20%)
  • Series B 1 (20%)
  • Series C 1 (20%)

Country

  • United Kingdom 4 (80%)
  • Switzerland 1 (20%)

Team

NameTitleInvestmentsLinksEmail
Brenig Preest
Brenig Preest Investment Director
Investment Director Total investments: 0 Find email
Christopher Thomas Evans Chairman
Chairman Total investments: 1 Find email
Owen Smith Investment Manager
Investment Manager Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. $65.6M / Post-IPO Equity / Jun 20, 2016
Rutherford Health is at the vanguard of advancing cancer care, building a series of oncology centres known as the Rutherford Cancer Centres.Offering world-class proton beam therapy, along with diagnostics, chemotherapy, radiotherapy, and holistic therapy, treatment at the centres will be available to medically-insured private patients,self-paying patients and patients referred by the NHS. Seed / Jan 01, 2016
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of productcandidates developed with its proprietary platform technology. $13.5M / Series B / Sep 29, 2015
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. $100M / Series C / Sep 01, 2015
Sphere Medical Holding PLC develops, manufactures, and commercializes monitoring products for critical care environments in the United Kingdom and internationally. The company offers microanalyser platforms that are used to measure clinical analytes, including pH, glucose, potassium, sodium, calcium, oxygen, Hct, and carbon dioxide. Its productsinclude analyzers for intensive care units and operating rooms; and cardiopulmonary bypass monitors, monitoring catheters, and intravenous anaesthetic analyzers. The company's products also include systems for the intermittent analysis and continuous monitoring of blood and other fluids; and sensors for catheters or other measurement probes. Its products provide healthcare professionals the information to manage therapy and optimize patient outcomes. Sphere Medical Holding PLC was formerly known as Sphere Medical Holding Ltd. and changed its name in November 2006. The company was founded in 2002 and is based in Cambridge, the United Kingdom. $19.4M / Post-IPO Equity / Apr 21, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Sudan
Pakistan
Madagascar
Russian Federation
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
China
Guernsey
Cameroon
Colombia
Armenia
Costa Rica
Czech Republic
Kuwait
Luxembourg
Marshall Islands
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Asia
Bermuda
Dominican Republic
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Arthurian Life Sciences invest in?

Arthurian Life Sciences invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity and Seed stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Arthurian Life Sciences?

Public channels for Arthurian Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Arthurian Life Sciences?

The team at Arthurian Life Sciences includes Brenig Preest (Investment Director), Christopher Thomas Evans (Chairman) and Owen Smith (Investment Manager). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Arthurian Life Sciences Arthurian Life Sciences Find emails